REGULATORY
Temporary Halts in Generic Product Marketing, JGA Accelerates Efforts in Collecting Information
The Japan Generic Medicines Association (JGA) is accelerating its efforts in collecting information regarding the issue of temporary suspensions in the marketing in Japan of certain generic products, such as the long-acting calcium channel blocker Atelec (cilnidipine), due to non-compliance…
To read the full story
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





